Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group.

Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group. by Hoban DJ and Jones RN. published in Chemotherapy 1995; 41 (1): 34-38

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1.

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1. by Doern GV, Jones RN, Gerlach EH, Washington JA, Biedenbach DJ, Brueggemann A, Erwin ME, Knapp C and Raymond J published in J. Clin. Microbiol. 1995; 33 (6): 1665-1667

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). by Cormican MG, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 51-54

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates. by Cormican MG and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (4): 227-230

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam.

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 57-60

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes.

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. by Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1995; 39 (7): 1636-1642

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: Real or perceived? Fluoroquinolone Resistance Surveillance Group.

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: Real or perceived? Fluoroquinolone Resistance Surveillance Group. by Jones RN, Kehrberg EN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1994; 19 (4): 203-215

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group. by Jones RN, Sader HS and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 20 (2): 93-98

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results. by Jones RN, Sutton LD, Cantrell HF and Lankford RB published in Diagn. Microbiol. Infect. Dis. 1994; 20 (3): 143-149

Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.

Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. by Houston AK and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 18 (1): 57-59